Partnership-based collaboration: The SynBio3 technology platform at the heart of innovation
The SynBio3 “polymer platform” technology platform, in collaboration with the IBMM’s “Polymers for Health and Biomaterials” department, the Montpellier Proteome Cluster, and the company MedinCell, have joined forces on the BIOPOLTRACE project.
As a winner of the 2020 Regional Research Innovation Platforms (PRRI) Call for Proposals, the BIOPOLTRACE project aims to develop new methods for monitoring the in vivo degradation of polymers used in the medical and pharmaceutical fields.As part of the regulatory requirements associated with bringing an implantable medical device or an injectable drug to market, the assessment of the degradation of the materials used, the identification of degradation products, and the question of the fate of these degradation products are central to obtaining CE marking or marketing authorization.
Currently, polymers such as polylactic acid (PLA) and polyethylene glycol (PEG) used in medical devices and drugs are subject to these requirements. However, current methods for monitoring polymer degradation—which rely on labeling techniques using radioactive or fluorescent probes—are limited and have numerous drawbacks.
BIOPOLTRACE aims to address these limitations by enabling the monitoring of the degradation of PLA-PEG copolymers in vivo using analytical methods such as MALDI-TOF mass spectrometry and liquid chromatography coupled with mass spectrometry (LC-MS, 2D LC-MS, SEC, etc.).
In addition, carbon-13 isotope labeling of the species under study will also be used, which will, in particular, improve the sensitivity of the analytical techniques.
Contacts: Vincent Darcos – Benjamin Nottelet